Cargando…

Tiliroside suppresses triple-negative breast cancer as a multifunctional CAXII inhibitor

Triple negative breast cancer (TNBC) is an aggressive subtype of breast cancer characterized by poor prognosis, early recurrence, and the lack of durable chemotherapy responses and specific targeted treatments. In this preclinical study, we examines Tiliroside (TS, C(30)H(26)O(13)), as one of the ma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Han, Rui, Yang, Hongxing, Ling, Changquan, Lu, Lingeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9685933/ https://www.ncbi.nlm.nih.gov/pubmed/36424626 http://dx.doi.org/10.1186/s12935-022-02786-6

Ejemplares similares

Tiliroside as a CAXII inhibitor suppresses liver cancer development and modulates E2Fs/Caspase-3 axis
por: Han, Rui, et al.
Publicado: (2021)

CAXII inhibitors: Potential sensitizers for immune checkpoint inhibitors in HCC treatment
por: Han, Rui, et al.
Publicado: (2023)

Valeric acid acts as a novel HDAC3 inhibitor against prostate cancer
por: Han, Rui, et al.
Publicado: (2022)

Potential of Dietary HDAC2i in Breast Cancer Patients Receiving PD-1/PD-L1 Inhibitors
por: Wang, Yuqian, et al.
Publicado: (2023)

CAXII Is a Sero-Diagnostic Marker for Lung Cancer
por: Kobayashi, Makoto, et al.
Publicado: (2012)

Enhancing HCC Treatment: innovatively combining HDAC2 inhibitor with PD-1/PD-L1 inhibition
por: Han, Rui, et al.
Publicado: (2023)

CAXII Is a Surrogate Marker for Luminal Breast Tumors Regulated by ER and GATA3
por: Porras, Lucas, et al.
Publicado: (2022)

Expression of transmembrane carbonic anhydrases, CAIX and CAXII, in human development
por: Liao, Shu-Yuan, et al.
Publicado: (2009)

Differential expression and function of CAIX and CAXII in breast cancer: A comparison between tumorgraft models and cells
por: Chen, Zhijuan, et al.
Publicado: (2018)

Inhibition of Melanoma Cell Migration and Invasion Targeting the Hypoxic Tumor Associated CAXII
por: Giuntini, Gaia, et al.
Publicado: (2020)

Role of the Hedgehog Pathway and CAXII in Controlling Melanoma Cell Migration and Invasion in Hypoxia
por: Giuntini, Gaia, et al.
Publicado: (2022)

Activation of Nrf2 Pathway Contributes to Neuroprotection by the Dietary Flavonoid Tiliroside
por: Velagapudi, Ravikanth, et al.
Publicado: (2018)

Synthesis and Biological Activity of trans-Tiliroside Derivatives as Potent Anti-Diabetic Agents
por: Zhu, Yujin, et al.
Publicado: (2010)

RAGE inhibitor TTP488 (Azeliragon) suppresses metastasis in triple-negative breast cancer
por: Magna, Melinda, et al.
Publicado: (2023)

AMPK/AS160 mediates tiliroside derivatives-stimulated GLUT4 translocation in muscle cells
por: Zhang, Chang, et al.
Publicado: (2018)

Antiprotozoal Activities of Tiliroside and other Compounds from Sphaeralcea angustifolia (Cav.) G. Don
por: Calzada, Fernando, et al.
Publicado: (2017)

Effect of Standardized Fractions and Tiliroside from Leaves of Tilia americana on Depression Tests in Mice
por: Chávez-Morales, Yadid, et al.
Publicado: (2019)

(89)Zr-Labeled Multifunctional Liposomes Conjugate Chitosan for PET-Trackable Triple-Negative Breast Cancer Stem Cell Targeted Therapy
por: Yang, Rui, et al.
Publicado: (2020)

Resibufogenin Suppresses Triple-Negative Breast Cancer Angiogenesis by Blocking VEGFR2-Mediated Signaling Pathway
por: Yang, Ting, et al.
Publicado: (2021)

p-Coumaric acid, Kaempferol, Astragalin and Tiliroside Influence the Expression of Glycoforms in AGS Gastric Cancer Cells
por: Radziejewska, Iwona, et al.
Publicado: (2022)

Role of the p-Coumaroyl Moiety in the Antioxidant and Cytoprotective Effects of Flavonoid Glycosides: Comparison of Astragalin and Tiliroside
por: Li, Xican, et al.
Publicado: (2017)

Tiliroside Attenuates NLRP3 Inflammasome Activation in Macrophages and Protects against Acute Lung Injury in Mice
por: Zhong, Chao, et al.
Publicado: (2023)

A Proof-of-Concept Inhibitor of Endothelial Lipase Suppresses Triple-Negative Breast Cancer Cells by Hijacking the Mitochondrial Function
por: Yang, Rongze, et al.
Publicado: (2022)

Role of BET Inhibitors in Triple Negative Breast Cancers
por: Khandekar, Durga, et al.
Publicado: (2020)

HDAC Inhibitors for the Therapy of Triple Negative Breast Cancer
por: Maccallini, Cristina, et al.
Publicado: (2022)

Tiliroside Combined with Anti-MUC1 Monoclonal Antibody as Promising Anti-Cancer Strategy in AGS Cancer Cells
por: Radziejewska, Iwona, et al.
Publicado: (2023)

Tiliroside Protects against Lipopolysaccharide-Induced Acute Kidney Injury via Intrarenal Renin–Angiotensin System in Mice
por: Yi, Xiaoli, et al.
Publicado: (2023)

MicroRNAs with Multiple Targets of Immune Checkpoints, as a Potential Sensitizer for Immune Checkpoint Inhibitors in Breast Cancer Treatment
por: Zhou, Huiling, et al.
Publicado: (2023)

New Perspectives for Resistance to PARP Inhibitors in Triple-Negative Breast Cancer
por: Han, Ye, et al.
Publicado: (2020)

Translating the role of PARP inhibitors in triple-negative breast cancer
por: Beniey, Michèle, et al.
Publicado: (2019)

Checkpoint inhibitor therapy for metastatic triple-negative breast cancer
por: Heeke, Arielle L., et al.
Publicado: (2021)

Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors
por: Abdou, Yara, et al.
Publicado: (2022)

Methionine deprivation suppresses triple-negative breast cancer metastasis in vitro and in vivo
por: Jeon, Hyein, et al.
Publicado: (2016)

Optimization of Extraction Conditions for Determination of Tiliroside in Tilia L. Flowers Using an LC-ESI-MS/MS Method
por: Pieczykolan, Aleksandra, et al.
Publicado: (2019)

AHNAK suppresses tumour proliferation and invasion by targeting multiple pathways in triple-negative breast cancer
por: Chen, Bo, et al.
Publicado: (2017)

Marizomib suppresses triple-negative breast cancer via proteasome and oxidative phosphorylation inhibition
por: Raninga, Prahlad V., et al.
Publicado: (2020)

Response and resistance to BET bromodomain inhibitors in triple negative breast cancer
por: Shu, Shaokun, et al.
Publicado: (2016)

MCAK Inhibitors Induce Aneuploidy in Triple-Negative Breast Cancer Models
por: Smith, John C., et al.
Publicado: (2023)

Pharmacological activation of FOXO3 suppresses triple-negative breast cancer in vitro and in vivo
por: Park, See-Hyoung, et al.
Publicado: (2016)

Triple-Negative Breast Cancer
por: Chu, Quyen D., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_jcc4bj8n6j2ihl9o1dgtjir0f9